Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction

J Clin Pharmacol. 2005 Oct;45(10):1145-52. doi: 10.1177/0091270005279580.

Abstract

Micafungin is an antifungal agent metabolized by arylsulfatase with secondary metabolism by catechol-O-methyltransferase. The objectives of this study were to estimate the pharmacokinetic parameters and plasma protein binding of micafungin in volunteers with moderate hepatic dysfunction (n = 8), volunteers with creatinine clearance < 30 mL/min (n = 9), and matched controls (n = 8 and n = 9, respectively). Single-dose micafungin pharmacokinetics were estimated using noncompartmental techniques. There was a statistically lower area under the observed micafungin concentration-time curve (AUC) from time 0 to infinity for subjects with moderate hepatic dysfunction as compared to control subjects (97.5 +/- 19 microg.h/mL vs 125.9 +/- 26.4 microg.h/mL, P = .03), although there was no difference in micafungin weight-adjusted clearance (10.9 +/- 1.7 mL/h/kg vs 9.8 +/- 1.8 mL/h/kg, P = .2). The difference in area under the concentration-time curve may be explained by the differences in body weight between subjects and controls. Renal dysfunction did not alter micafungin pharmacokinetics.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Area Under Curve
  • Echinocandins
  • Female
  • Humans
  • Infusions, Intravenous
  • Kidney Diseases / metabolism*
  • Lipopeptides
  • Lipoproteins / administration & dosage
  • Lipoproteins / blood
  • Lipoproteins / pharmacokinetics*
  • Liver Diseases / metabolism*
  • Male
  • Metabolic Clearance Rate
  • Micafungin
  • Middle Aged
  • Peptides, Cyclic / administration & dosage
  • Peptides, Cyclic / blood
  • Peptides, Cyclic / pharmacokinetics*

Substances

  • Echinocandins
  • Lipopeptides
  • Lipoproteins
  • Peptides, Cyclic
  • Micafungin